Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit .REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.
加利福尼亞州雷德伍德市，2024年11月19日 (環球新聞社) -- Codexis公司（納斯達克股票代碼: CDXS）是領先的酶解決方案供應商，致力於高效可擴展治療製造，今天宣佈公司將參加2024年12月3日至5日在紐約市舉辦的派傑投資第36屆年度醫療保健大會。
Management will participate in a fireside chat on Tuesday, December 3, 2024, at 11:00 am ET. A live webcast of the event will be available in the Investor Relations section of the Company's website, . A replay will be archived for 90 days following the event.
管理團隊將於2024年12月3日星期二上午11:00參與爐邊聊天。活動的現場網絡直播將在公司網站的投資者關係部分提供。活動結束後將有現場重播可供90天訪問。
About Codexis
關於Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit .
Codexis是一家領先的酶解決方案提供商，爲高效可伸縮的治療製造業提供支持，利用自有的CodeEvolver技術平台來發現、開發和增強新穎的高性能酶和其他蛋白質類。Codexis的酶解決了與小分子製藥製造和核酸合成相關的現實挑戰。該公司目前正在開發其專有的ECO合成製造平台，以通過酶路線實現RNAi治療藥物的規模化生產。Codexis獨特的酶可以帶來諸如更高產量、降低能源使用和廢物產生、改善製造效率以及在基因組和診斷應用中更敏感等方面的改進。欲了解更多信息，請訪問。
For More Information
更多信息
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
投資者聯繫人
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
媒體聯繫
Lauren Musto
(650) 421-8205
media@codexis.com